Scopus Biopharma

Scopus Biopharma P/TBV

Price to Tangible Book Value (P/TBV) of Scopus Biopharma (SCPS) as of Nov 19, 2026.

P/TBV

-0.00

YoY

-156.89%

Last updated:

Price to Tangible Book Value (P/TBV) of Scopus Biopharma is 2022 -0.00 . Price to Tangible Book Value (P/TBV) of Scopus Biopharma was 2021 0.01 . It decreases by -156.89% lower compared to the previous year.

The Scopus Biopharma P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2017
0.25 USD
Jan 1, 2018
-4.74 USD
Jan 1, 2019
-0.30 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
0.01 USD
Jan 1, 2022
-0.00 USD
The Scopus Biopharma P/TBV history
YEARP/TBVYoY
-0.00-156.89%
0.01-145.58%
-0.01-95.48%
-0.30-93.57%
-4.74-2,007.40%
0.25—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scopus Biopharma stock

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Scopus Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Scopus Biopharma

All Key Metrics — Scopus Biopharma